Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion.
Animals
Cell Line, Tumor
Collagen
/ metabolism
Discoidin Domain Receptor 1
/ antagonists & inhibitors
Disease Models, Animal
Extracellular Matrix
/ immunology
Female
Gene Deletion
Gene Knockout Techniques
Humans
Immunocompetence
/ immunology
Immunotherapy
Mice
T-Lymphocytes
/ cytology
Triple Negative Breast Neoplasms
/ immunology
Tumor Escape
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
18
10
2019
accepted:
22
09
2021
pubmed:
5
11
2021
medline:
5
3
2022
entrez:
4
11
2021
Statut:
ppublish
Résumé
Immune exclusion predicts poor patient outcomes in multiple malignancies, including triple-negative breast cancer (TNBC)
Identifiants
pubmed: 34732895
doi: 10.1038/s41586-021-04057-2
pii: 10.1038/s41586-021-04057-2
pmc: PMC8839149
mid: NIHMS1773797
doi:
Substances chimiques
Collagen
9007-34-5
DDR1 protein, human
EC 2.7.10.1
Ddr1 protein, mouse
EC 2.7.10.1
Discoidin Domain Receptor 1
EC 2.7.10.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
673-678Subventions
Organisme : NCI NIH HHS
ID : R01 CA212674
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM114142
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA206529
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA051008
Pays : United States
Organisme : NICHD NIH HHS
ID : P50 HD105328
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA054174
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA205965
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA246707
Pays : United States
Organisme : NIH HHS
ID : S10 OD021805
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Gruosso, T. et al. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J. Clin. Invest. 129, 1785–1800 (2019).
doi: 10.1172/JCI96313
Cox, T. R. The matrix in cancer. Nat. Rev. Cancer 21, 217–238 (2021).
doi: 10.1038/s41568-020-00329-7
Bejarano, L., Jordao, M. J. C. & Joyce, J. A. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 11, 933–959 (2021).
doi: 10.1158/2159-8290.CD-20-1808
Chen, Y. et al. Type I collagen deletion in αSMA
doi: 10.1016/j.ccell.2021.02.007
Leitinger, B. Discoidin domain receptor functions in physiological and pathological conditions. Int. Rev. Cell Mol. Biol. 310, 39–87 (2014).
doi: 10.1016/B978-0-12-800180-6.00002-5
Valiathan, R. R., Marco, M., Leitinger, B., Kleer, C. G. & Fridman, R. Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metastasis Rev. 31, 295–321 (2012).
doi: 10.1007/s10555-012-9346-z
Hidalgo-Carcedo, C. et al. Collective cell migration requires suppression of actomyosin at cell-cell contacts mediated by DDR1 and the cell polarity regulators Par3 and Par6. Nat. Cell Biol. 13, 49–58 (2011).
doi: 10.1038/ncb2133
Gao, H. et al. Multi-organ site metastatic reactivation mediated by non-canonical discoidin domain receptor 1 signaling. Cell 166, 47–62 (2016).
doi: 10.1016/j.cell.2016.06.009
Edwards, D. N. et al. Selective glutamine metabolism inhibition in tumor cells improves anti-tumor T lymphocyte activity in triple-negative breast cancer. J Clin. Invest. 131, e140100 (2021).
doi: 10.1172/JCI140100
Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24, 1550–1558 (2018).
doi: 10.1038/s41591-018-0136-1
Jimenez-Sanchez, A., Cast, O. & Miller, M. L. Comprehensive benchmarking and integration of tumor microenvironment cell estimation methods. Cancer Res. 79, 6238–6246 (2019).
doi: 10.1158/0008-5472.CAN-18-3560
Vogel, W. F., Aszodi, A., Alves, F. & Pawson, T. Discoidin domain receptor 1 tyrosine kinase has an essential role in mammary gland development. Mol. Cell. Biol. 21, 2906–2917 (2001).
doi: 10.1128/MCB.21.8.2906-2917.2001
Takai, K. et al. Discoidin domain receptor 1 (DDR1) ablation promotes tissue fibrosis and hypoxia to induce aggressive basal-like breast cancers. Genes Dev. 32, 244–257 (2018).
doi: 10.1101/gad.301366.117
Carafoli, F. et al. Structure of the discoidin domain receptor 1 extracellular region bound to an inhibitory Fab fragment reveals features important for signaling. Structure 20, 688–697 (2012).
doi: 10.1016/j.str.2012.02.011
Vogel, W. F. Ligand-induced shedding of discoidin domain receptor 1. FEBS Lett. 514, 175–180 (2002).
doi: 10.1016/S0014-5793(02)02360-8
Agarwal, G., Mihai, C. & Iscru, D. F. Interaction of discoidin domain receptor 1 with collagen type 1. J. Mol. Biol. 367, 443–455 (2007).
doi: 10.1016/j.jmb.2006.12.073
Ruggeri, J. M. et al. Discoidin domain receptor 1 (DDR1) is necessary for tissue homeostasis in pancreatic injury and pathogenesis of pancreatic ductal adenocarcinoma. Am. J. Pathol. 190, 1735–1751 (2020).
doi: 10.1016/j.ajpath.2020.03.020
Ambrogio, C. et al. Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. Nat. Med. 22, 270–277 (2016).
doi: 10.1038/nm.4041
Salmon, H. et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J. Cell. Invest. 122, 899–910 (2021).
Kaur, A. et al. Remodeling of the collagen matrix in aging skin promotes melanoma metastasis and affects immune cell motility. Cancer Discov. 9, 64–81 (2019).
Ray, A. & Provenzano, P. P. Aligned forces: Origins and mechanisms of cancer dissemination guided by extracellular matrix architecture. Curr. Opin. Cell Biol. 72, 63–71 (2021).
Tomko, L. A. et al. Targeted matrisome analysis identifies thrombospondin-2 and tenascin-C in aligned collagen stroma from invasive breast carcinoma. Sci. Rep. 8, 12941 (2018).
doi: 10.1038/s41598-018-31126-w
Dunlap, S. M. et al. Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models. Cancer Prev. Res. 5, 930–942 (2012).
doi: 10.1158/1940-6207.CAPR-12-0034
Mertins, P. et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55–62 (2016).
doi: 10.1038/nature18003
Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14, 7 (2013).
doi: 10.1186/1471-2105-14-7
Fougner, C., Bergholtz, H., Norum, J. H. & Sorlie, T. Re-definition of claudin-low as a breast cancer phenotype. Nat. Commun. 11, 1787 (2020).
doi: 10.1038/s41467-020-15574-5
Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013).
doi: 10.1186/gb-2013-14-4-r36
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
doi: 10.1186/s13059-014-0550-8
Ashburner, M. et al. Gene ontology: tool for the unification of biology. Nat. Genet. 25, 25–29 (2000).
doi: 10.1038/75556
Suzuki, R. & Shimodaira, H. Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics 22, 1540–1542 (2006).
doi: 10.1093/bioinformatics/btl117
Raudvere, U. et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists. Nucleic Acids Res. 47, W191–W198 (2019).
doi: 10.1093/nar/gkz369
Li, T. et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 48, W509–W514 (2020).
doi: 10.1093/nar/gkaa407
Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773–782 (2019).
doi: 10.1038/s41587-019-0114-2
Erikson, A., Ortegren, J., Hompland, T., de Lange Davies, C. & Lindgren, M. Quantification of the second-order nonlinear susceptibility of collagen I using a laser scanning microscope. J. Biomed. Opt. 12, 044002 (2007).
doi: 10.1117/1.2772311
Wu, B. et al. PPARγ inhibition boosts efficacy of immune checkpoint immunotherapy against murine melanoma in a sexually dimorphic manner. Int. J. Biol. Sci. 16, 1526–1535 (2020).
doi: 10.7150/ijbs.42966
Meng, W. et al. Efficient generation of monoclonal antibodies from single rhesus macaque antibody secreting cells. MAbs 7, 707–718 (2015).
doi: 10.1080/19420862.2015.1051440
Gui, X. et al. Disrupting LILRB4/APOE interaction by an efficacious humanized antibody reverses T-cell suppression and blocks AML development. Cancer Immunol. Res. 7, 1244–1257 (2019).
doi: 10.1158/2326-6066.CIR-19-0036